|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From Toronto General Hospital, Toronto, Ontario, Canada.
Correspondence to: F. Griffith Pearson, MD, Toronto General Hospital, Eaton North 10233, 200 Elizabeth St, Toronto, Ontario, Canada M5G-2C4; e-mail: pearson{at}user.rose.com
Survival following surgical resection of non-small cell lung cancer (NSCLC) has improved since the 1960s, although the 5-year survival rate remains low. This article provides an overview of the role of surgery for NSCLC stages I-III, with a focus on optimizing long-term survival in those patients with resectable disease. Topics explored include diagnosis and staging, indications for resection, types of resection, and indications for adjuvant therapy. A review of the literature indicates a clear survival advantage for complete resection, and is suggestive of an advantage for mediastinal lymph node dissection (vs lymph node sampling) and neoadjuvant therapy (vs adjuvant therapy).
This article has been cited by other articles:
![]() |
M. Licker, A. Spiliopoulos, J.-G. Frey, J. Robert, L. Hohn, M. de Perrot, and J.-M. Tschopp Risk Factors for Early Mortality and Major Complications Following Pneumonectomy for Non-small Cell Carcinoma of the Lung* Chest, June 1, 2002; 121(6): 1890 - 1897. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Elia, S. Griffo, M. Gentile, R. Costabile, and G. Ferrante Surgical treatment of lung cancer invading chest wall: a retrospective analysis of 110 patients Eur. J. Cardiothorac. Surg., August 1, 2001; 20(2): 356 - 360. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |